WallStreetZen

NYSE: EVH
Evolent Health Inc Stock Forecast, Predictions & Price Target

Analyst price target for EVH

Based on 3 analysts offering 12 month price targets for Evolent Health Inc.
Min Forecast
$20.00-24.1%
Avg Forecast
$23.67-10.18%
Max Forecast
$27.00+2.47%

Should I buy or sell EVH stock?

Based on 3 analysts offering ratings for Evolent Health Inc.
Strong Buy
Strong Buy
3 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

EVH stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDate
Canaccord Genuity
Top 24%
77
Strong BuyMaintains$27.00+2.47%2021-08-05
Anonymous
Canaccord Genuity
Strong BuyMaintains$24.00-8.92%2021-03-01
BTIG
Top 39%
62
Strong BuyInitiates Coverage On$20.00-24.10%2021-01-07

1 of 1

Forecast return on equity

Is EVH forecast to generate an efficient return?
Company
-1.85%
Industry
12.31%
Market
60.49%
EVH's Return on Equity is forecast to be low in 3 years (-1.85%); analysts are not confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is EVH forecast to generate an efficient return on assets?
Company
-0.88%
Industry
7.14%
Market
16.9%
EVH is forecast to generate lower Return on Assets (-0.88%) than the US Health Information Services industry average (7.14%)
Forecast

EVH earnings per share forecast

What is EVH's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$0.27-63.85%
Avg 2 year Forecast
-$0.15-80.41%
Avg 3 year Forecast
-$0.13-82.43%

EVH revenue forecast

What is EVH's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$888.4M-8.76%
Avg 2 year Forecast
$1.0B+5.1%
Avg 3 year Forecast
$1.2B+22.32%
EVH's revenue is forecast to grow at a rate of 2.93% per year, which is not exceptional
Forecast

EVH revenue growth forecast

How is EVH forecast to perform vs Health Information Services companies and vs the US market?
Company
2.93%
Industry
15.67%
Market
14.3%
EVH's revenues are forecast to grow slower (2.93% per year) than the US Health Information Services industry average (15.67%)
Forecast
EVH's revenues are forecast to grow slower (2.93% per year) than the US market average (14.3%)
Forecast

Evolent Health Stock Forecast FAQ

Is Evolent Health Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NYSE: EVH) stock is to Strong Buy EVH stock.

Out of 3 analysts, 3 (100%) are recommending EVH as a Strong Buy, 0 (0%) are recommending EVH as a Buy, 0 (0%) are recommending EVH as a Hold, 0 (0%) are recommending EVH as a Sell, and 0 (0%) are recommending EVH as a Strong Sell.

What is EVH's earnings growth forecast for 2021-2023?

(NYSE: EVH) Evolent Health's forecast annual earnings growth rate of N/A is not forecast to beat the US Health Information Services industry's average forecast earnings growth rate of 27.97%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 23.36%.

Evolent Health's earnings in 2021 is -$70,887,000.On average, 4 Wall Street analysts forecast EVH's earnings for 2021 to be $-23,344,129, with the lowest EVH earnings forecast at $-24,434,976, and the highest EVH earnings forecast at $-21,816,943. On average, 4 Wall Street analysts forecast EVH's earnings for 2022 to be $-12,653,827, with the lowest EVH earnings forecast at $-24,434,976, and the highest EVH earnings forecast at $-2,618,033.

In 2023, EVH is forecast to generate $-11,344,810 in earnings, with the lowest earnings forecast at $-11,344,810 and the highest earnings forecast at $-11,344,810.

What is EVH's revenue growth forecast for 2021-2023?

(NYSE: EVH) Evolent Health's forecast annual revenue growth rate of 2.93% is not forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 15.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.3%.

Evolent Health's revenue in 2021 is $973,644,000.On average, 3 Wall Street analysts forecast EVH's revenue for 2021 to be $77,526,594,218, with the lowest EVH revenue forecast at $77,101,076,562, and the highest EVH revenue forecast at $78,299,263,072. On average, 3 Wall Street analysts forecast EVH's revenue for 2022 to be $89,298,493,054, with the lowest EVH revenue forecast at $87,128,143,565, and the highest EVH revenue forecast at $91,109,299,323.

In 2023, EVH is forecast to generate $103,935,916,452 in revenue, with the lowest revenue forecast at $103,935,916,452 and the highest revenue forecast at $103,935,916,452.

What is EVH's forecast return on assets (ROA) for 2021-2023?

(NYSE: EVH) forecast ROA is -0.88%, which is lower than the forecast US Health Information Services industry average of 7.14%.

What is EVH's Price Target?

According to 3 Wall Street analysts that have issued a 1 year EVH price target, the average EVH price target is $23.67, with the highest EVH stock price forecast at $27.00 and the lowest EVH stock price forecast at $20.00.

On average, Wall Street analysts predict that Evolent Health's share price could stay at $23.67 by Aug 5, 2022. The average Evolent Health stock price prediction forecasts a potential downside of N/A from the current EVH share price of $26.35.

What is EVH's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: EVH) Evolent Health's current Earnings Per Share (EPS) is -$0.74. On average, analysts forecast that EVH's EPS will be $-0.27 for 2021, with the lowest EPS forecast at $-0.28, and the highest EPS forecast at $-0.25. On average, analysts forecast that EVH's EPS will be $-0.15 for 2022, with the lowest EPS forecast at $-0.28, and the highest EPS forecast at $-0.03. In 2023, EVH's EPS is forecast to hit $-0.13 (min: $-0.13, max: $-0.13).

What is EVH's forecast return on equity (ROE) for 2021-2023?

(NYSE: EVH) forecast ROE is -1.85%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.